Organogenesis Holdings Inc. (ORGO): Price and Financial Metrics
ORGO Price/Volume Stats
Current price | $2.42 | 52-week high | $4.50 |
Prev. close | $2.43 | 52-week low | $1.79 |
Day low | $2.36 | Volume | 413,534 |
Day high | $2.46 | Avg. volume | 1,069,179 |
50-day MA | $3.20 | Dividend yield | N/A |
200-day MA | $2.85 | Market Cap | 317.78M |
ORGO Stock Price Chart Interactive Chart >
ORGO POWR Grades
- Value is the dimension where ORGO ranks best; there it ranks ahead of 98.52% of US stocks.
- The strongest trend for ORGO is in Stability, which has been heading up over the past 179 days.
- ORGO ranks lowest in Momentum; there it ranks in the 7th percentile.
ORGO Stock Summary
- With a price/sales ratio of 0.67, ORGANOGENESIS HOLDINGS INC has a higher such ratio than just 23.54% of stocks in our set.
- In terms of twelve month growth in earnings before interest and taxes, ORGANOGENESIS HOLDINGS INC is reporting a growth rate of -65.74%; that's higher than merely 20.46% of US stocks.
- The volatility of ORGANOGENESIS HOLDINGS INC's share price is greater than that of 80.8% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to ORGANOGENESIS HOLDINGS INC are BRC, RFIL, IART, HUN, and ASYS.
- Visit ORGO's SEC page to see the company's official filings. To visit the company's web site, go to organogenesis.com.
ORGO Valuation Summary
- In comparison to the median Healthcare stock, ORGO's price/sales ratio is 82.5% lower, now standing at 0.7.
- ORGO's EV/EBIT ratio has moved NA NA over the prior 82 months.
Below are key valuation metrics over time for ORGO.
Stock | Date | P/S | P/B | P/E | EV/EBIT |
---|---|---|---|---|---|
ORGO | 2023-09-18 | 0.7 | 1.1 | 30.6 | 20.9 |
ORGO | 2023-09-15 | 0.7 | 1.2 | 32.0 | 21.8 |
ORGO | 2023-09-14 | 0.7 | 1.3 | 34.0 | 23.0 |
ORGO | 2023-09-13 | 0.7 | 1.3 | 34.0 | 23.0 |
ORGO | 2023-09-12 | 0.8 | 1.3 | 34.5 | 23.3 |
ORGO | 2023-09-11 | 0.7 | 1.3 | 34.1 | 23.1 |
ORGO Growth Metrics
- Its 5 year net income to common stockholders growth rate is now at -19903.07%.
- The 3 year net income to common stockholders growth rate now stands at 205.83%.
- The 4 year net cashflow from operations growth rate now stands at -7237.35%.

The table below shows ORGO's growth in key financial areas (numbers in millions of US dollars).
Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
---|---|---|---|
2022-09-30 | 464.935 | 35.007 | 60.741 |
2022-06-30 | 461.829 | 57.404 | 73.103 |
2022-03-31 | 463.624 | 64.868 | 85.046 |
2021-12-31 | 468.059 | 61.978 | 94.902 |
2021-09-30 | 446.308 | 70.306 | 61.701 |
2021-06-30 | 433.354 | 49.599 | 70.058 |
ORGO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- ORGO has a Quality Grade of B, ranking ahead of 77.36% of graded US stocks.
- ORGO's asset turnover comes in at 1.426 -- ranking 12th of 681 Pharmaceutical Products stocks.
- VRTX, ACOR, and TPST are the stocks whose asset turnover ratios are most correlated with ORGO.
The table below shows ORGO's key quality metrics over time.
Period | Asset Turnover | Gross Margin | ROIC |
---|---|---|---|
2021-06-30 | 1.426 | 0.760 | 0.406 |
2021-03-31 | 1.409 | 0.752 | 0.298 |
2020-12-31 | 1.401 | 0.742 | 0.166 |
2020-09-30 | 1.373 | 0.732 | 0.035 |
2020-06-30 | 1.315 | 0.709 | -0.159 |
2020-03-31 | 1.377 | 0.707 | -0.204 |
ORGO Price Target
For more insight on analysts targets of ORGO, see our ORGO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
Average Price Target | $26.75 | Average Broker Recommendation | 1.12 (Strong Buy) |
Organogenesis Holdings Inc. (ORGO) Company Bio
Organogenesis Holdings Inc. operates as a holding company. The Company, through its subsidiaries, focuses on development, manufacturing, and commercializing drugs and medicines for wound care, surgical, and sports medicine markets. Organogenesis Holdings serves customers in the United States and Switzerland.
Latest ORGO News From Around the Web
Below are the latest news stories about ORGANOGENESIS HOLDINGS INC that investors may wish to consider to help them evaluate ORGO as an investment opportunity.
Organogenesis Holdings, Inc. (ORGO) Q2 2023 Earnings Call TranscriptOrganogenesis Holdings, Inc. (ORGO) Q2 2023 Earnings Conference Call August 09, 2023, 17:00 ET Company Participants Gary Gillheeney - President, CEO & Chair David Francisco - CFO Conference Call Participants Ryan Zimmerman - BTIG Andrew Ranieri - Morgan Stanley Presentation Operator Welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2023 Earnings Conference Call for Organogenesis Holdings Inc. [Operator Instructions]. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly. Before we begin, I would like to remind everyone that our remarks tod... |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayWe're starting off the day with a breakdown of the biggest pre-market stock movers traders should watch on Thursday morning! |
Why Shares of Organogenesis Holdings Are Dropping ThursdayShares of Organogenesis Holdings (NASDAQ: ORGO) were down more than 19% as of 11 a.m. on Thursday after the company announced second-quarter earnings and withdrew annual guidance after the markets closed on Wednesday. Organogenesis is a healthcare company that makes advanced care products for the wound-healing process. The company operates in two segments, Advanced Wound Care and Surgical & Sports Medicine, and both saw declines. |
Q2 2023 Organogenesis Holdings Inc Earnings CallQ2 2023 Organogenesis Holdings Inc Earnings Call |
Organogenesis (ORGO) Q2 2023 Earnings Call TranscriptORGO earnings call for the period ending June 30, 2023. |
ORGO Price Returns
1-mo | -6.92% |
3-mo | -29.24% |
6-mo | 28.04% |
1-year | -25.77% |
3-year | -37.14% |
5-year | N/A |
YTD | -10.04% |
2022 | -70.89% |
2021 | 22.71% |
2020 | 56.55% |
2019 | N/A |
2018 | 0.00% |
Continue Researching ORGO
Want to see what other sources are saying about Organogenesis Holdings Inc's financials and stock price? Try the links below:Organogenesis Holdings Inc (ORGO) Stock Price | Nasdaq
Organogenesis Holdings Inc (ORGO) Stock Quote, History and News - Yahoo Finance
Organogenesis Holdings Inc (ORGO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...